Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICE Protocol in Refractory Germ Cell Tumors
NCT00864318Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Mar 2009
- Primary completion
- Oct 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide, carboplatin and etoposide in germ cell tumor (GCT), sponsored by Institut Claudius Regaud. Primary endpoints: Complete response rate (by chemotherapy or chemotherapy + surgery) at 6 months and Pathological complete response rate at 6 months. Started Mar 2009; status: completed.
02
Drugs
paclitaxelifosfamidecarboplatinetoposide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00864318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00864318.